Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 67

1.

Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells.

Fehniger TA, Suzuki K, Ponnappan A, VanDeusen JB, Cooper MA, Florea SM, Freud AG, Robinson ML, Durbin J, Caligiuri MA.

J Exp Med. 2001 Jan 15;193(2):219-31.

2.

IL-15 and IL-2: a matter of life and death for T cells in vivo.

Li XC, Demirci G, Ferrari-Lacraz S, Groves C, Coyle A, Malek TR, Strom TB.

Nat Med. 2001 Jan;7(1):114-8.

PMID:
11135625
3.

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group..

N Engl J Med. 2000 Nov 30;343(22):1594-602.

4.

Infliximab: a review of its use in the management of rheumatoid arthritis.

Markham A, Lamb HM.

Drugs. 2000 Jun;59(6):1341-59. Review.

PMID:
10882166
5.

CD40-CD40 ligand-independent activation of CD8+ T cells can trigger allograft rejection.

Jones ND, Van Maurik A, Hara M, Spriewald BM, Witzke O, Morris PJ, Wood KJ.

J Immunol. 2000 Jul 15;165(2):1111-8.

7.

Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice.

Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M, Matsuki N, Charrier K, Sedger L, Willis CR, Brasel K, Morrissey PJ, Stocking K, Schuh JC, Joyce S, Peschon JJ.

J Exp Med. 2000 Mar 6;191(5):771-80.

8.

High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism.

Ziolkowska M, Koc A, Luszczykiewicz G, Ksiezopolska-Pietrzak K, Klimczak E, Chwalinska-Sadowska H, Maslinski W.

J Immunol. 2000 Mar 1;164(5):2832-8.

9.

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P.

Lancet. 1999 Dec 4;354(9194):1932-9.

PMID:
10622295
10.

Asialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection.

Trambley J, Bingaman AW, Lin A, Elwood ET, Waitze SY, Ha J, Durham MM, Corbascio M, Cowan SR, Pearson TC, Larsen CP.

J Clin Invest. 1999 Dec;104(12):1715-22.

11.

Role of tumour necrosis factor alpha in experimental arthritis: separate activity of interleukin 1beta in chronicity and cartilage destruction.

van den Berg WB, Joosten LA, Kollias G, van De Loo FA.

Ann Rheum Dis. 1999 Nov;58 Suppl 1:I40-8. Review.

12.

Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance.

Wells AD, Li XC, Li Y, Walsh MC, Zheng XX, Wu Z, Nuñez G, Tang A, Sayegh M, Hancock WW, Strom TB, Turka LA.

Nat Med. 1999 Nov;5(11):1303-7.

PMID:
10545998
13.
14.

IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice.

Zheng XX, Steele AW, Hancock WW, Kawamoto K, Li XC, Nickerson PW, Li Y, Tian Y, Strom TB.

J Immunol. 1999 Oct 1;163(7):4041-8.

15.

Production of interleukin-7 and interleukin-15 by fibroblast-like synoviocytes from patients with rheumatoid arthritis.

Harada S, Yamamura M, Okamoto H, Morita Y, Kawashima M, Aita T, Makino H.

Arthritis Rheum. 1999 Jul;42(7):1508-16.

17.

Human monocytes constitutively express membrane-bound, biologically active, and interferon-gamma-upregulated interleukin-15.

Musso T, Calosso L, Zucca M, Millesimo M, Ravarino D, Giovarelli M, Malavasi F, Ponzi AN, Paus R, Bulfone-Paus S.

Blood. 1999 May 15;93(10):3531-9. Erratum in: Blood. 2012 Sep 6;120(10):2155.

18.

Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response.

Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA, Suzuki K, Wechser M, Goodsaid F, Caligiuri MA.

J Immunol. 1999 Apr 15;162(8):4511-20.

19.

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ.

N Engl J Med. 1999 Jan 28;340(4):253-9.

20.

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, Nuki G, Pavelka K, Rau R, Rozman B, Watt I, Williams B, Aitchison R, McCabe D, Musikic P.

Arthritis Rheum. 1998 Dec;41(12):2196-204.

PMID:
9870876

Supplemental Content

Support Center